Olcegepant

Drug Profile

Olcegepant

Alternative Names: BIBN 4096; BIBN 4096BS

Latest Information Update: 19 Nov 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antimigraines; Dipeptides; Quinazolines
  • Mechanism of Action Calcitonin gene-related peptide antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Migraine

Most Recent Events

  • 07 Nov 2007 Pharmacodynamics data from an in vivo study presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007)
  • 08 Nov 2004 A clinical study has been added to the pharmacokinetics section
  • 13 Oct 2004 A clinical study has been added to the pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top